To the Editor, We recently reported the presence of autoantibodies (auto-Abs) against at least 14 of the 17 type I interferons (IFNs) underlying life-threatening COVID-19 pneumonia in at least 10% of a large cohort of patients [1]. Patients with inborn errors of the TLR3-and IRF7-dependent production and amplification of type I IFNs are also prone to life-threatening COVID-19 pneumonia [2]. These findings suggest that the early administration of IFN-α2 or-β, the two clinically available human type I IFNs, might be beneficial to patients with inborn errors of, or auto-Abs against type I IFN infected with SARS-CoV-2. We recently reported the safety and apparent efficacy of early administration of a single subcutaneous injection of Peg-IFN-α2a in two unrelated patients with autosomal dominant deficiencies of TLR3 and IRF3, whose genetic disorders were diagnosed before SARS-CoV-2 infection [3]. Both patients were treated in the first 7 days of SARS-CoV-2 infection and recovered without developing severe COVID-19 pneumonia.